- The report contains detailed information about Pharmaxis Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Pharmaxis Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Pharmaxis Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Pharmaxis Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Pharmaxis Ltd. business.
About Pharmaxis Ltd.
Pharmaxis Ltd., a specialty pharmaceutical company, focuses on the development of products for the diagnosis and treatment of chronic respiratory and immune disorders primarily in Australia.
The company is developing Bronchitol, its proprietary, inhaled dry powder mannitol formulation, for the treatment of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and bronchiectasis; and for the treatment of other acute and chronic pulmonary conditions.
Bronchitol for Cystic fibrosis: The company has completed Phase III clinical trial of Bronchitol in patients with CF in Europe and Australia.
Bronchitol for Bronchiectasis: The company has completed Phase III clinical trial of Bronchitol for bronchiectasis in Europe and Australia. It is seeking marketing approval.
Bronchitol for other pulmonary indications: Bronchitol has potential application to other pulmonary conditions, such as COPD and patients within hospital intensive care units.
The company has developed Aridol (mannitol bronchial challenge test), as a tool for the detection of airway hyperresponsiveness and to assist in the diagnosis and management of asthma. The Aridol test mimics the bronchoconstriction that can occur in inflamed airways in people with asthma. Aridol may also be used to determine the minimum effective doses of inhaled corticosteroid required for optimum control of asthma. It supplies Aridol in Australia. It has also received marketing approval to Aridol in Germany, France, the United Kingdom, Italy, the Netherlands, Belgium, Denmark, Greece, Finland, Ireland, Norway, Sweden, Portugal, and South Korea.
The companys preclinical pipeline is focused on treatments for fibrotic and inflammatory diseases, including asthma and other pulmonary conditions. PXS25 has been identified as an antifibrotic agent and PXS4159 has been identified as an anti-inflammatory agent. PXS25 is in development for the treatment of pulmonary fibrosis (IPF). Preclinical trials have been completed with PXS25 and intend to commence Phase I clinical trials. Preclinical trials are in progress with PXS4159 to determine its suitability for Phase I human clinical trials. PXS25 is an inhibitor of the mannose 6 phosphate receptor and PXS4159 is an inhibitor of semicarbazide sensitive amine oxidase/vascular adhesion protein-1.
The company identifies competition from AstraZeneca; Methapharm, Inc.; Gilead Sciences, Inc.; Novartis AG; AOP Orphan; Pharmaceuticals AG; and Inspire Pharmaceuticals, Inc.
The company was incorporated in 1998 under the name Praxis Pharmaceuticals Australia Pty Ltd. in 1998 and changed its name to Pharmaxis Pty Ltd. in 2002. Further, it changed its name to Pharmaxis Ltd. in 2003.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. PHARMAXIS LTD. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. PHARMAXIS LTD. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. PHARMAXIS LTD. SWOT ANALYSIS
4. PHARMAXIS LTD. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. PHARMAXIS LTD. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Pharmaxis Ltd. Direct Competitors
5.2. Comparison of Pharmaxis Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Pharmaxis Ltd. and Direct Competitors Stock Charts
5.4. Pharmaxis Ltd. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Pharmaxis Ltd. Industry Position Analysis
6. PHARMAXIS LTD. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. PHARMAXIS LTD. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. PHARMAXIS LTD. ENHANCED SWOT ANALYSIS2
9. AUSTRALIA PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. PHARMAXIS LTD. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. PHARMAXIS LTD. PORTER FIVE FORCES ANALYSIS2
12. PHARMAXIS LTD. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Pharmaxis Ltd. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Pharmaxis Ltd. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Pharmaxis Ltd. Major Shareholders
Pharmaxis Ltd. History
Pharmaxis Ltd. Products
Revenues by Segment
Revenues by Region
Pharmaxis Ltd. Offices and Representations
Pharmaxis Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Pharmaxis Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Pharmaxis Ltd. Capital Market Snapshot
Pharmaxis Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Pharmaxis Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Pharmaxis Ltd. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Pharmaxis Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Pharmaxis Ltd. 1-year Stock Charts
Pharmaxis Ltd. 5-year Stock Charts
Pharmaxis Ltd. vs. Main Indexes 1-year Stock Chart
Pharmaxis Ltd. vs. Direct Competitors 1-year Stock Charts
Pharmaxis Ltd. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?